Interleukin Genetics, Inc. (Interleukin) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the personalized health market. The Company has two primary segments to its business. The first is a personalized health segment primarily focused on researching and developing genetic tests that target the role that genetically determined variations in the inflammatory response have on health and disease. The second segment, comprising the Interleukin brands consumer products business, focuses on developing, selling and marketing nutritional supplements and products into retail consumer channels. (Source: 10-K)
Myriad Genetics, Inc. is a biotechnology company focused on the development and marketing of therapeutic and molecular diagnostic products. As of June 30, 2007, the Company had four drug candidates in seven clinical trials, and a number of other drug candidates that are in late-stage preclinical development. Its major drug development programs include Flurizan for the treatment of Alzheimer’s disease, Azixa for the treatment of primary and metastatic brain tumors, MPC-2130 for the treatment of hematologic cancers, MPC-0920 for the treatment of thrombosis, and Vivecon for the treatment of acquired immune deficiency syndrome (AIDS). The Company’s revenues, for the fiscal year ended June 30, 2007, consisted primarily of sales of molecular diagnostic products (92%) and research payments (8%). Its commercial molecular diagnostic products include BRACAnalysis, COLARIS, COLARIS AP and MELARIS. On April 10, 2008, the Company acquired NaturNorth Technologies, LLC.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory